Jun 24, 2025 8:30am EDT Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
May 28, 2025 6:30am EDT Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone
May 08, 2025 6:30am EDT Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
Mar 31, 2025 8:30am EDT Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
Feb 13, 2025 6:30am EST Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Feb 06, 2025 8:30am EST Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
